| Q47767122 | Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk |
| Q45977434 | An in vitro model for preclinical testing of thrombogenicity of resorbable metallic stents. |
| Q45111432 | Antiplatelet therapy in atherosclerotic cardiovascular disease |
| Q28185093 | Aspirin in patients with coronary artery disease: is it simply irresistible? |
| Q28194943 | Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease |
| Q28192302 | Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system |
| Q35842977 | Effects of atrioventricular asynchrony on platelet activation: implication of thromboembolism in paced patients. |
| Q34394985 | Effects of microtopographic patterns on platelet adhesion and activation on titanium oxide surfaces |
| Q41256836 | Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells |
| Q33922853 | Fibrinogen receptor antagonists: design and clinical applications |
| Q33735581 | Future directions in thrombolysis. |
| Q35043956 | Histamine blood concentration in ischemic heart disease patients |
| Q41364350 | Hypothesis: is soluble P-selectin a new marker of platelet activation? |
| Q28192888 | In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease |
| Q28167456 | Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke |
| Q28191508 | Interaction between smoking and the glycoprotein IIIa P1(A2) polymorphism in non-ST-elevation acute coronary syndromes |
| Q33410913 | Low platelet counts after liver transplantation predict early posttransplant survival: the 60-5 criterion |
| Q35636842 | P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions |
| Q51450354 | Perioperative catecholamine changes in cardiac risk patients. |
| Q74012794 | PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement |
| Q51444149 | Platelet expression of CD62P in hypotrophic newborns. |
| Q34434798 | Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies |
| Q40673523 | Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy |
| Q33747438 | Platelets and stroke |
| Q46878409 | Postprandial lipemia is associated with platelet and monocyte activation and increased monocyte cytokine expression in normolipemic men. |
| Q77718674 | Raised levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the plasma of patients with ischaemic heart disease and hyperlipidaemia |
| Q50921101 | Relation between mitral regurgitation and platelet activation. |
| Q73995202 | Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy |
| Q34559219 | Resveratrol, a phenolic antioxidant with effects on blood platelet functions |
| Q33634204 | Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension |
| Q43061592 | Smoking and atherosclerotic cardiovascular disease: part II: role of cigarette smoking in cardiovascular disease development |
| Q77511782 | The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction |
| Q43292681 | The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro. |
| Q43135408 | The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. |
| Q45420752 | The polyphenol-rich extracts from black chokeberry and grape seeds impair changes in the platelet adhesion and aggregation induced by a model of hyperhomocysteinemia. |
| Q74840150 | Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome: a possible mechanism of immune-mediated thrombosis |